FierceBiotech

BioTime and the California Institute for Regenerative Medicine Sign Distribution Agreement for GMP-Compliant Stem Cell Lines

BioTime, Inc. and the California Institute for Regenerative Medicine Sign Distribution Agreement for GMP-Compliant Human Embryonic Stem Cell Lines ALAMEDA, Calif ...
Yahoo Finance

BioTime CEO Shares Updates On Spinal Cord Injury And Dry AMD Therapies

BioTime, Inc. (NYSE: BTX) is a clinical-stage biotechnology company focused on regenerative medicine and pluripotent stem cell technologies. It was established by Dr. Michael D. West, the original ...
FiercePharma

BioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia™ in Europe

ALAMEDA, Calif.--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced it has submitted a Clinical ...
MedCity News

Regenerative medicine startup Cell Targeting sold to BioTime

Stem cell technology developer Cell Targeting has sold its assets to BioTime (AMEX:BTX) in a deal worth about $2.3 million. BioTime will pay $250,000 in cash as well as 262,000 shares of BioTime’s ...
FiercePharma

BioTime and OncoCyte Corporation Publish Data on the Gene COL10A1 as a Marker and Potential Diagnostic for a Wide Array of Human Cancers

BioTime and OncoCyte Corporation Publish Data on the Gene as a Marker and Potential Diagnostic for a Wide Array of Human Cancers BioTime, Inc.Peter Garcia, 510-521-3390 ext. 367Chief Financial ...
FierceBiotech

BioTime Announces Second Quarter 2012 Financial Results and Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the second quarter ended June 30, ...
Forbes

BioTime Makes Key Clinical Progress; SOTP Now $4.40/Share

On August 2, 2018, BioTime Inc. (NYSE: BTX; $2.31; market capitalization: $293 million) announced results for 2Q18. BioTime primary clinical programs Renevia and OpRegen progressed on research and ...
Business Wire

BioTime Signs Agreements with Jade Therapeutics for Ophthalmological Drug Delivery Applications of HyStem ® Technology

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an ...
The Motley Fool

The Bearish Case for BioTime

A light R&D budget, a technology that may not be commercially viable, and a stock prone to promotion make one investor skeptical of BioTime's prospects. Sid Haksar manages a concentrated, ...
Business Wire

Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Acquires Geron’s Embryonic Stem Cell Assets

MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) jointly announced today the closing of the transactions under the Asset ...
The Business Journals

BioTime acquires stem cell assets from Geron, raises $10 million

BioTime Inc. picked up 400 patents and applications plus other intellectual property dealing with human embryonic stem cells from Geron Inc. BioTime Inc. picked up 400 patents and applications plus ...